Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) has earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $205.80.

BLTE has been the subject of several research analyst reports. HC Wainwright upped their price target on shares of Belite Bio from $200.00 to $214.00 and gave the company a “buy” rating in a research report on Wednesday. Benchmark reiterated a “buy” rating on shares of Belite Bio in a research report on Friday. Cantor Fitzgerald boosted their target price on shares of Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday. Mizuho set a $220.00 target price on Belite Bio in a report on Friday. Finally, Zacks Research raised Belite Bio from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 20th.

More Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
• Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
• Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
• Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing

Insider Activity at Belite Bio

In related news, insider Hendrik Peter Scholl sold 10,000 shares of the stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $145.24, for a total value of $1,452,400.00. Following the completion of the sale, the insider directly owned 15,000 shares of the company’s stock, valued at approximately $2,178,600. This represents a 40.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Hao-Yuan Chuang sold 367 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $180.35, for a total value of $66,188.45. Following the sale, the chief financial officer owned 93,433 shares of the company’s stock, valued at $16,850,641.55. The trade was a 0.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 20,732 shares of company stock valued at $2,990,116. Company insiders own 13.29% of the company’s stock.

Institutional Trading of Belite Bio

A number of hedge funds have recently made changes to their positions in BLTE. Caitong International Asset Management Co. Ltd grew its position in Belite Bio by 28,200.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock valued at $45,000 after purchasing an additional 282 shares in the last quarter. Bank of America Corp DE increased its stake in Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after buying an additional 257 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Belite Bio in the 4th quarter worth approximately $103,000. Persistent Asset Partners Ltd purchased a new stake in Belite Bio in the 4th quarter worth approximately $108,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of Belite Bio during the 2nd quarter valued at $147,000. 0.53% of the stock is owned by hedge funds and other institutional investors.

Belite Bio Trading Down 2.1%

NASDAQ BLTE opened at $162.80 on Friday. Belite Bio has a 1 year low of $60.00 and a 1 year high of $200.00. The company has a market cap of $6.53 billion, a PE ratio of -59.63 and a beta of -1.22. The stock’s 50-day moving average price is $152.50 and its two-hundred day moving average price is $159.86.

Belite Bio (NASDAQ:BLTE) last announced its earnings results on Tuesday, June 30th. The company reported ($0.54) EPS for the quarter. Research analysts forecast that Belite Bio will post -3.17 EPS for the current fiscal year.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.